Revolutionizing at-home health testing: En Carta Diagnostics secures €5 million for Lyme disease and STI molecular tests

En Carta Diagnostics, a DeepTech startup based in Paris, has recently secured €5 million in financing, with the first closing including €3 million in equity led by Blue Forest Ventures, along with participation from Ring Capital and existing investors CentraleSupélec Venture, 50 Partners Health, and a group of business angels. Additionally, the closing involved €2 million in non-dilutive financing from Bpifrance and other partners. This follows a previous funding round in May 2024, where the company raised €1.5 million in pre-Seed funding led by CentraleSupélec Venture.

Co-founder and CEO of En Carta Diagnostics, Guillaume Horreard, expressed that this funding brings the company closer to its goal of revolutionizing access to testing by enabling patients to conduct reliable molecular tests at home. Founded in 2022 by Horreard and Margot Karlikow, En Carta Diagnostics is focused on developing a new generation of home molecular diagnostics that combine the precision of a laboratory PCR with the simplicity of a rapid test.

The company’s proprietary platform is designed to make high-performance molecular diagnostics accessible outside of a traditional laboratory setting. En Carta Diagnostics is currently addressing Lyme disease, a prevalent vector-borne disease in the Northern Hemisphere, with 1.2 million cases reported annually. The company’s technology aims to provide early detection, improve patient outcomes, and alleviate strain on healthcare systems.

En Carta Diagnostics emphasizes that its technology offers a rapid Point-of-Need molecular diagnostic platform in an affordable cassette format, utilizing aptamers to detect specific targets with high precision. The company is focusing on expanding its technology to include early detection of Lyme disease and STI screening.

Having achieved its first-in-human milestone, En Carta Diagnostics is conducting clinical trials for its flagship product in both Boston (USA) and Bialystock (Poland). The company received FDA Breakthrough Device Designation in January 2026, allowing for an accelerated regulatory pathway to the US market. En Carta has also partnered with AAZ to develop and commercialize rapid molecular tests for chlamydia and gonorrhea in Europe, with a significant commercial partnership valued at €13 million.

With the recent financing, En Carta Diagnostics plans to advance regulatory certification in Europe and the US, enhance industrialization through partnerships, and accelerate the commercial launch and market expansion of its molecular testing solutions. The company aims to bring its innovative products to patients and clinicians across Europe and the US, starting with early Lyme disease detection and expanding into other applications like STI screening.